Form 4: Cellectar Biosciences Executive Granted Stock Options Following Shareholder Approval
SEC Form 4
Darrell Shane Lea, Chief Commercial Officer of Cellectar Biosciences, received stock options for 260,000 shares after shareholder approval of the amended 2021 Stock Incentive Plan.
Summary
- Darrell Shane Lea, the Chief Commercial Officer of Cellectar Biosciences, was granted stock options to purchase 260,000 shares of common stock.
- The options were granted on June 14, 2024, following shareholder approval of Cellectar's amended 2021 Stock Incentive Plan.
- The options have an exercise price of $2.65 per share.
- The options vest over three years from December 15, 2023, with one-third vesting on the first anniversary and the remainder in 24 equal monthly installments.
Sentiment
Score: 7
Explanation: The granting of stock options is a positive sign, indicating confidence in the executive and aligning their interests with shareholders. The shareholder approval further strengthens this positive sentiment.
Positives
- The granting of stock options to a key executive aligns their interests with those of the shareholders.
- Shareholder approval of the amended 2021 Stock Incentive Plan indicates support for the company's compensation strategy.
Industry Context
Stock options are a common form of executive compensation in the biotechnology industry, used to incentivize performance and align executive interests with shareholder value.
Stakeholder Impact
- Shareholders: The granting of stock options can align executive interests with shareholder value.
- Employees: The stock incentive plan can motivate employees and attract talent.
Key Dates
| Date | Description |
|---|---|
| December 15, 2023 | Date the option was contingently granted and vesting period begins. |
| June 14, 2024 | Date of shareholder approval of Cellectar's amended 2021 Stock Incentive Plan and grant date of the options. |
| December 15, 2033 | Expiration date of the stock options. |
Keywords
stock options, Cellectar Biosciences, CLRB, Darrell Shane Lea, Chief Commercial Officer, stock incentive plan, shareholder approval, executive compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.